BIOGEN INC. |
Mercato chiuso -
Altri mercati azionari
|
Dopo chiusura 22:00:01 | |||
| 211,8 EUR | +0,33% |
|
210,2 | -0,78% |
Attività
- vendite di farmaci (73,7%): per il trattamento della sclerosi multipla, della psoriasi cronica negli adulti, dell'artrite reumatoide, dei tumori, ecc;
- royalties (17,2%) ;
- altro (9,1%): principalmente ricavi da accordi di partnership.
Numero di dipendenti: 7 570
Vendite per attività
| USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
|---|---|---|---|---|---|
Innovative Therapies
100,0
%
| 10 173 | 100,0 % | 9 836 | 100,0 % | -3,32% |
Vendite per regione
| USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
|---|---|---|---|---|---|
United States
55,2
%
| 5 532 | 54,4 % | 5 434 | 55,2 % | -1,77% |
Europe
21,8
%
| 2 413 | 23,7 % | 2 140 | 21,8 % | -11,34% |
Germany
8,8
%
| 926 | 9,1 % | 868 | 8,8 % | -6,28% |
Asia
8,8
%
| 720 | 7,1 % | 863 | 8,8 % | +19,97% |
Other
5,4
%
| 583 | 5,7 % | 531 | 5,4 % | -8,87% |
Dirigenti
| Dirigenti | Titolo | Età | Da |
|---|---|---|---|
| Chief Executive Officer | 64 | 14/11/22 | |
| Director of Finance/CFO | 60 | 15/08/20 | |
Nicole Murphy
COO | Chief Operating Officer | - | 01/01/15 |
Jane Grogan
CTO | Chief Tech/Sci/R&D Officer | 57 | 02/10/23 |
Chuck Triano
IRC | Investor Relations Contact | - | 10/04/23 |
Michael Hencke
IRO | Public Communications Contact | - | 01/07/12 |
Michael Dambach
TRE | Treasurer | 57 | 01/01/07 |
| General Counsel | - | - | |
Robert Kilo
PRN | Corporate Officer/Principal | - | - |
Rachid Izzar
PRN | Corporate Officer/Principal | - | 01/01/21 |
Amministratori
| Amministratori | Titolo | Età | Da |
|---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 01/01/10 |
William Hawkins
BRD | Director/Board Member | 70 | 19/06/19 |
Caroline Dorsa
CHM | Chairman | 64 | 03/01/10 |
Eric Rowinsky
BRD | Director/Board Member | 67 | 20/03/10 |
| Chief Executive Officer | 64 | 14/11/22 | |
Maria Freire
BRD | Director/Board Member | 69 | 02/06/21 |
| Director/Board Member | 54 | 01/01 | |
Jesus Mantas
BRD | Director/Board Member | 55 | 19/06/19 |
Susan Langer
BRD | Director/Board Member | 33 | 26/06/23 |
Classe di azioni
| Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
|---|---|---|---|---|---|
| Azione A | 1 | 169 396 895 | 145 366 956 ( 85,81 %) | 23 800 000 ( 14,05 %) | 85,81 % |
Partecipazioni
| Nome | Azioni | % | Valorizzazione |
|---|---|---|---|
DENALI THERAPEUTICS INC. 8.94% | 12 751 365 | 8.94% | 236 665 334 $ |
SAGE THERAPEUTICS, INC. 10.37% | 6 241 473 | 10.37% | 69 342 765 $ |
| 14 652 466 | 7.06% | 8 263 991 $ |
Coordinate società
Società del gruppo
| Nome | Categoria e settore |
|---|---|
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. |
Biotechnology
|
Biogen International GmbH
 Biogen International GmbH Pharmaceuticals: MajorHealth Technology Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland. |
Pharmaceuticals: Major
|
Settore
Vendite per regione
Revisioni EPS
| Variaz. 1 gen. | Capi. | |
|---|---|---|
| -0,12% | 92,26 Mrd | |
| -2,63% | 38,11 Mrd | |
| +66,54% | 26,51 Mrd | |
| -13,02% | 15,75 Mrd | |
| -5,27% | 13,36 Mrd | |
| -10,50% | 11,65 Mrd | |
| -49,11% | 10,12 Mrd | |
| +187,82% | 9,78 Mrd | |
| +0,67% | 8,84 Mrd |
- Borsa valori
- Azioni
- Azione BIIB
- Azione IDP
- Società Biogen Inc.
